Comparative Study Between Hyperbaric Therapy and Intravesical Dimethyl Sulfoxide Instillation for Interstitial Cystitis

NCT ID: NCT01069263

Last Updated: 2011-04-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-02-28

Study Completion Date

2015-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the efficacy of hyperbaric oxygen therapy (HBOT) to intravesical Dimethyl Sulfoxide (DMSO) instillation for the treatment of patients who suffers from Interstitial Cystitis / Painful bladder syndrome.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Interstitial cystitis / painful bladder syndrome (IC/PBS) presents as a pelvic pain condition associated with urinary urgency and frequency. These symptoms impair significantly the patient's quality of life. The etiology is yet not obvious. The current acceptable theory is injury or dysfunction of the Mucus (Glycosaminoglycans) layer that covers the inner surface of the urinary bladder. Abnormal diffusion of toxins from the urine to the walls of the bladder leads to inflammation, pain and scarring.

Many types of treatments were described but most of them were not evaluated in well designed randomized controlled studies. For now, there is no one single treatment that gives good outcome to every patient. Therefore, the treatment of patients with IC/PBS is challenging. In this study, we will compare the efficacy of hyperbaric oxygen therapy (HBOT) to intravesical dimethyl sulfoxide (DMSO) instillation for the treatment of patients who suffers from IC/PBS.

Patients with IC (NIDDK criteria) will be randomized to have either DMSO instillation or HBOT.

Before and after treatments the patients will fill out questionnaires (O'Leary-Sant Interstitial Cystitis Symptom and Problem Index), visual analogue scale for pain and bladder diaries. In addition, urodynamics will be performed before and after treatments. In case of incomplete symptoms remission, patients will be crossed over to have the other treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Interstitial Cystitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intravesical DMSO instillation

50 mls of 50% DMSO instilled once a week to the urinary bladder for 12 consecutive weeks.

Group Type ACTIVE_COMPARATOR

DMSO

Intervention Type DRUG

50 mls of 50% DMSO instilled once a week to the urinary bladder for 12 consecutive weeks.

Hyperbaric Oxygen Therapy (HBOT)

Overall 60 treatments (5 days per weeks for 12 weeks). 90 minutes every session. Pressure of 2 atm. Inhalation of 100% oxygen.

Group Type EXPERIMENTAL

Hyperbaric Oxygen Therapy

Intervention Type OTHER

60 treatments (12 weeks - 5 days a week) of hyperbaric (pressure of 2 atmospheres) with 100% oxygen inhalation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hyperbaric Oxygen Therapy

60 treatments (12 weeks - 5 days a week) of hyperbaric (pressure of 2 atmospheres) with 100% oxygen inhalation.

Intervention Type OTHER

DMSO

50 mls of 50% DMSO instilled once a week to the urinary bladder for 12 consecutive weeks.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

HBOT Hyperbaric chamber Hyperbaric therapy dimethyl sulfoxide

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* NIDDK diagnosis of interstitial cystitis

Exclusion Criteria

* Previous treatment of hyperbaric therapy
* Contraindication for hyperbaric therapy (mid-ear pathology, abnormal chest X-ray, Claustrophobia, pregnancy
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assaf-Harofeh Medical Center

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Assaf-Harofeh Medical Center

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kobi Stav, MD

Role: PRINCIPAL_INVESTIGATOR

Assaf Harofe Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Assaf Harofe Medical Center

Zeriffin, , Israel

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Kobi Stav, MD

Role: CONTACT

+972-89779400

Shay Efrati, MD

Role: CONTACT

+972-577346364

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Kobi Stav, MD

Role: primary

+972-577346778

Shay Efrati, MD

Role: backup

+972-577346364

References

Explore related publications, articles, or registry entries linked to this study.

Perez-Marrero R, Emerson LE, Feltis JT. A controlled study of dimethyl sulfoxide in interstitial cystitis. J Urol. 1988 Jul;140(1):36-9. doi: 10.1016/s0022-5347(17)41478-9.

Reference Type BACKGROUND
PMID: 3288775 (View on PubMed)

van Ophoven A, Rossbach G, Oberpenning F, Hertle L. Hyperbaric oxygen for the treatment of interstitial cystitis: long-term results of a prospective pilot study. Eur Urol. 2004 Jul;46(1):108-13. doi: 10.1016/j.eururo.2004.03.002.

Reference Type RESULT
PMID: 15183555 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://www.painful-bladder.org/index.html

International Painful Bladder Foundation

http://www.ichelp.org

Interstitial Cystitis Association

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

04/10

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

PK and Safety of SI-722 in IC/BPS
NCT04208087 COMPLETED PHASE1/PHASE2
Interstitial Cystitis
NCT00056251 COMPLETED PHASE2